Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel vs Pegylated Liposomal Doxorubicin in HIV-related Kaposi Sarcoma
NCT05411237Phase 3Not yet recruiting
- Sponsor
- AIDS Malignancy Consortium
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 3 trial of paclitaxel, doxorubicin in Kaposi sarcoma (KS), sponsored by AIDS Malignancy Consortium. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
paclitaxeldoxorubicin
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT05411237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411237.